Clinical trials: Cisplatin Nephrotoxicity
Cisplatin Adverse Reaction
Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity
Approximately one-third of all patients treated with cisplatin develop renal dysfunction after a single dosage of cisplatin. Germline genetic polymorphisms may cause variations in cisplatin pharmacokinetics and in the ability of…
- Trial name
- NCT05247671
- Testing
- ERCC1, OCT2
- Where
- Egypt
- Volunteers
- 89 people
- Sponsor
- Ain Shams University
Cisplatin Nephrotoxicity
Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity
Cisplatin is a major anti-neoplastic drug used for the treatment of solid tumors. Its chief dose limiting side effect is nephrotoxicity. Twenty percent of patients receiving high-dose cisplatin undergo severe renal dysfunction.
- Trial name
- NCT02760901
- Testing
- Acetazolamide, Acetylcysteine, Mannitol
- Volunteers
- 52 people
- Sponsor
- Ain Shams University
Nephrotoxicity
Cisplatin Disposition and Kidney Injury
This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a…
- Trial name
- NCT03817970
- Testing
- Granisetron, Ondansetron, Palonosetron
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Cancer, Drug Toxicity
Tc-99m Renography and Cisplatin-induced Nephrotoxicity
Cisplatin is a heavy-metal complex widely used in the treatment of a variety of malignancies, including small cell and non-small cell lung cancer, ovarian, bladder, head and neck, esophageal, cervical and germ cell tumors.
- Conditions
- Cancer, Drug Toxicity, Kidney Failure
- Trial name
- NCT00213642
- Volunteers
- 20 people
- Sponsor
- University Hospital, Rouen
Head and Neck Cancer
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
The project is designed to test new biomarkers that are more sensitive than the current standard in detecting injury to the proximal kidney tubule and will establish better criteria for when kidney safety concerns may halt…
- Trial name
- NCT01936376
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Foundation for the National Institutes of Health
Osteosarcoma, Nephrotoxicity
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Osteosarcoma is the most common type of bone cancer in children, adolescents and young adults. Treatment with surgery and a combination of three conventional chemotherapy drugs can cure nearly two-thirds patients with…
- Conditions
- Osteosarcoma, Nephrotoxicity, Ototoxicity
- Trial name
- NCT01848457
- Testing
- Pantoprazole, High-dose methotrexate infusion duration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Cisplatin Adverse Reaction, Cisplatin Nephrotoxicity
Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients
Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients
- Conditions
- Cisplatin Adverse Reaction, Cisplatin Nephrotoxicity, Cisplatin Induced Peripheral Neuropathy, Cancer Patients
- Trial name
- NCT06297369
- Testing
- N acetyl cysteine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Cisplatin-induced Nephrotoxicity
Magnesium Supplementation for the Prevention of Cisplatin-Induced Nephrotoxicity
This prospective, randomized, open-label study evaluated whether intravenous magnesium sulphate added to standard hydration could reduce cisplatin-associated renal toxicity in adult patients with solid tumors receiving weekly…
- Trial name
- NCT07874373
- Testing
- Magnesium sulphate, Furosemide, Saline (0.9% NaCl)
- Where
- Romania
- Volunteers
- 43 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Drug Toxicity
Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity
Cisplatin is one of the first-line drugs used against many malignancies, such as lung cancer, head and neck cancer, esophageal cancer, gastric cancer, colorectal cancer, urothelial cancer, bladder cancer and testicular cancer.
- Trial name
- NCT06019520
- Testing
- N-Acetylcysteine, Chemotherapy
- Where
- Pakistan
- Volunteers
- 70 people
- Sponsor
- Foundation University Islamabad
Solid Tumors, Cisplatin Nephrotoxicity
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
Patients with cancer who receive platinum-based chemotherapy are at increased risk of kidney injury caused by these drugs. This form of toxicity can lead to treatment delays, dose reductions, or permanent discontinuation of…
- Trial name
- DAPA-ARMOR (NCT07018622)
- Testing
- Dapagliflozin 10 MG Oral Tablet
- Where
- Mexico
- Volunteers
- 46 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Cisplatin Nephrotoxicity, Nephrotoxicity
Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity
To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes
- Trial name
- NCT07564479
- Testing
- Alpha-Lipoic Acid (ALA)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Minia University
Cancer
Investigation of Cisplatin-Related Kidney Toxicity
The purpose of this study is to identify novel biomarkers of kidney injury in patients receiving cisplatin. This study will also collect DNA for future analysis.
- Trial name
- NCT00984035
- Testing
- urine samples (biomarkers), blood samples (biomarkers), blood sample (DNA)
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Chicago
Cystic Fibrosis
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
The project is designed to test new biomarkers that are more sensitive than the current standard in detecting injury to the proximal kidney tubule and will establish better criteria for when kidney safety concerns may halt…
- Trial name
- NCT01543620
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Foundation for the National Institutes of Health
Cisplatin Nephrotoxicity, Cisplatin Adverse Reaction
Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction
This trial is a multicenter, combined hydration, multiple-dose, dose-escalation phase Ib clinical study, designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of the injection product…
- Trial name
- NCT07824843
- Testing
- GMDTC 1 mg/ml, GMDTC 2mg/ml, GMDTC 3mg/ml
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.
Cis-Platinum Nephropathy, Mannitol Adverse Reaction
The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial
This study include cancer patients who had received chemotherapy that include cisplatin. Patients were randomly assigned to either a mannitol 20 g intravenous single dose after cisplatin or a placebo (saline).
- Trial name
- MACIN (NCT04251689)
- Testing
- Mannitol
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Chemotherapeutic Agent Toxicity, Renal Toxicity
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Renal Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00695032
- Testing
- cisplatin, ifosfamide, laboratory biomarker analysis
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Cisplatin Adverse Reaction
Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients
The goal of this [ type of study: intervential study is to compare between different doses of magnesium to prevent cisplatin induced nephrotoxicity.] In 75 participant population with head and neck cancer recieved cisplatin it…
- Trial name
- NCT05586009
- Testing
- cisplatin with hydration magnesium, cisplatin 40 mg/m²
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tanta University
Acute Kidney Injury
Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity
The purpose of this study is to determine whether magnesium preloading reduce incident of cisplatin induced acute kidney injury in head and neck cancer who receiving low dose cisplatin (40 mg/m2 weekly for 7 weeks).
- Trial name
- PRAGMATIC (NCT02481518)
- Testing
- Magnesium, Control
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Mahidol University
Muscle-Invasive Bladder Carcinoma
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer.
- Trial name
- NCT06215976
- Testing
- Metformin Hydrochloride 500 MG
- Where
- Egypt
- Volunteers
- 78 people
- Sponsor
- Cairo University
Upper GI Cancer, Cisplatin Adverse Reaction
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Cisplatin is a potent chemotherapeutic agent that has been widely used to treat many solid tumours. acute renal failure, despite conservative fluid and electrolyte management, frequently reported adverse event and limiting…
- Trial name
- NCT01829178
- Testing
- Silymarin, chemotherapy
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Tehran University of Medical Sciences